October 2-6, 2013
Suicide Risk Doubles Among HIV-Infected People Taking Efavirenz, Study Finds
Lipids Respond Well to Switch From Boosted PI to Rilpivirine/Tenofovir/Emtricitabine (Complera), Study Finds
Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?
More IDWeek 2013 Headlines:
TheBodyPRO.com is an independent website not associated with this conference.
IDWeek 2013 is the second annual combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). It features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases -- including HIV -- across a patient's lifespan.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|